Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development Service Platform
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
Peptide Drug Conjugate (PDC) R&D Service Platform
Antibody R&D Service
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
Routes of Drug Administration Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D Platform
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Recruitment
Talent Development
Talent Development
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
HomeClient CenterMedicilon SupportIND 100
IND 100 Publications
Sep 18,2024
Medicilon congratulates Genfleet Therapeutics on the approval and launch of their KRAS G12C inhibitor, Fuzerelisib.
Recently, Genfleet Therapeutics launched its KRAS G12C inhibitor, Dabote® (Fuzerelisib Tablets, GFH925/IBI351). Shanghai Medicilon Inc. (Medicilon) leveraged its well-established pharmacokinetics research platform to provide early-stage animal pharmacokinetic services for Fuzerelisib.
See More
Medicilon congratulates Genfleet Therapeutics on the approval and launch of their KRAS G12C inhibitor, Fuzerelisib.
Sep 18,2024
Value repeatedly verified! Medicilon congratulates its partner, EpimAb Biotherapeutics, on the overseas authorization of their BCMA×CD3 bispecific antibody EMB-06
On September 4th, EpimAb Biotherapeutics (EpimAb) announced that it has reached a licensing agreement with Vignette Bio, Inc. (Vignette Bio) regarding EpimAb's BCMA-targeted T-cell engager (TCE) molecule, EMB-06. As a partner of EpimAb, Shanghai Medicilon Inc. (Medicilon) congratulates EpimAb on the licensing of its BCMA×CD3 bispecific antibody EMB-06 for international markets.
See More
Value repeatedly verified! Medicilon congratulates its partner, EpimAb Biotherapeutics, on the overseas authorization of their BCMA×CD3 bispecific antibody EMB-06
Sep 10,2024
Medicilon supports its partner Jingye Medicine & Chemical Co in obtaining approval for the market launch of its gadopentetate chemical raw material
Recently, Suzhou Jingye Medicine & Chemical Co., Ltd. (Jingye) successfully obtained the "Approval Notice for the Market Launch of Chemical Raw Materials" (Notice No. 2024YS00864) issued by the National Medical Products Administration (NMPA) for its gadopentetate chemical raw material.
See More
Medicilon supports its partner Jingye Medicine & Chemical Co in obtaining approval for the market launch of its gadopentetate chemical raw material
Jun 19,2024
Medicilon helps Keye Life's new drug targeting RNA helicase obtain dual approval in China and the United States
Medicilon provided efficacy studies and safety evaluation services that comply with both Chinese GLP and U.S. GLP standards for KY1, facilitating its successful dual IND approval in both China and the United States.
See More
Medicilon helps Keye Life's new drug targeting RNA helicase obtain dual approval in China and the United States
Jun 14,2024
Medicilon assists Insilico Medicine in obtaining approval for MAT2A inhibitor in both China and the United States
Recently, ISM3412, a class 1 new drug developed by InSilico Medicine Cayman TopCo (Insilico Medicine), received implied approval for clinical trials in China. As a strategic partner of Insilico Medicine, Medicilon provided preclinical research services for ISM3412, including pharmacokinetics and safety evaluation tests​.
See More
Medicilon assists Insilico Medicine in obtaining approval for MAT2A inhibitor in both China and the United States
Jun 11,2024
Medicilon helps Sungening Biological's first innovative drug SG1001 oral tablet obtain IND approval in China
Recently, Sungening Biological's (Sungening) first innovative drug SG1001 successfully obtained the implicit clinical trial approval from the National Medical Products Administration (Acceptance Number: CXHL2400203).
See More
Medicilon helps Sungening Biological's first innovative drug SG1001 oral tablet obtain IND approval in China
Jun 11,2024
Medicilon assists the world's first, Leado Pharma's IBD treatment FIC new drug IND application approved by the US FDA
On May 11, Leado Pharma (Leado) announced that the company's independently developed First-in-class new drug LD09163 tablets for treating inflammatory bowel disease has obtained IND approval from the US FDA and officially entered the clinical development stage.
See More
Medicilon assists the world's first, Leado Pharma's IBD treatment FIC new drug IND application approved by the US FDA
Jun 11,2024
Medicilon congratulates - Treatable and Accessible! Adult and adolescent Type A and Type B influenza! AnDiCon Bio's pill cures influenza with the new drug Madoxanavir - Phase III successful research
Medicilon, as a partner of AnDiCon, provided formulation research services for the 'pediatric version' of the anti-influenza Class 1 Madoxanavir granules for influenza, assisting in its rapid advancement in preclinical research and development processes.
See More
Medicilon congratulates - Treatable and Accessible! Adult and adolescent Type A and Type B influenza! AnDiCon Bio's pill cures influenza with the new drug Madoxanavir - Phase III successful research
Mar 19,2024
Medicilon assists Biotime obtain approval for its first dual-filing innovative drug in China and the United States
Shanghai Medicilon Inc. (Medicilon) provides one-stop preclinical R&D services from target to IND application for the research and development of BIOT-001, and fully empowers BIOT-001 tablets to obtain the approval in China and United States.
See More
Medicilon assists Biotime obtain approval for its first dual-filing innovative drug in China and the United States
Mar 11,2024
Medicilon assists Shanghai Institute of Biological Products' innovative ADC drug obtain clinical approval
On February 19, SIBP-A17, the second class I innovative antibody drug conjugate (ADC) independently developed by China National Pharmaceutical Group's Shanghai Institute of Biological Products, received a clinical trial approval notice from the National Medical Products Administration (NMPA).
See More
Medicilon assists Shanghai Institute of Biological Products' innovative ADC drug obtain clinical approval
Stock Code
688202

Global

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->